[Press Release] STEP LEARNING Website, an Information Portal Site Responding to the "Want to Know" of People with Rare and Intractable Diseases, is Now Open.
ASrid, a non-profit organization, is pleased to announce the launch of the STEP LEARNING website. This information portal responds to the "want to know" needs of patients, families, and other stakeholders in rare and intractable diseases (NANBYO).
STEP stands for "Strategic Translational Action for Empowering Patients. " STEP aims to "implement strategic bridges to empower patients and their families."
The first in the STEP series is STEP LEARNING, which covers seven topics in rare and intractable diseases (NANBYO) that are relevant across all disease areas.
- Rare and intractable diseases in general
- Genomics (genes)
- Clinical trials/trials
- Pharmaceuticals
- Law/Policy
- Social Welfare
- Patient Collaboration/PPI
STEP LEARNING is a non-profit project operated with the support of pharmaceutical companies, medical device manufacturers, CROs, and medical IT companies. We will continue to open our doors to a wide range of stakeholders, including pharmaceutical companies, information-related companies, and other industries involved in this field.
In the future, we will also publish domain-specific pages as part of the STEP series.
We hope that promoting STEP activities will become a "correct index" and "selectable index" of the necessary information for all people involved in the disease and help match the information that patients, families, and other people "want to know" with the knowledge that stakeholders "want to deliver.
STEP LEARNING website: https://www.step-rd.info/
For more information, please see the press release.
Introduction of STEP projects in RDD2022
https://rddjapan.info/2022/wp-content/uploads/sites/5/2022/01/pnl10_STEP.pdf
*Press release from Takeda Pharmaceutical Company Limited, a member of the STEP community.
https://www.takeda.com/ja-jp/announcements/2022/step-learning/